SG Americas Securities LLC Grows Stock Holdings in Vaxcyte, Inc. $PCVX

SG Americas Securities LLC increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 129.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,558 shares of the company’s stock after buying an additional 14,421 shares during the period. SG Americas Securities LLC’s holdings in Vaxcyte were worth $921,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its stake in Vaxcyte by 12.1% during the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after buying an additional 534,552 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Vaxcyte by 42.4% during the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock valued at $99,770,000 after acquiring an additional 913,761 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Vaxcyte by 5.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,011,140 shares of the company’s stock worth $97,903,000 after purchasing an additional 142,086 shares during the last quarter. Jennison Associates LLC boosted its stake in Vaxcyte by 24.3% in the 2nd quarter. Jennison Associates LLC now owns 1,399,299 shares of the company’s stock worth $45,491,000 after purchasing an additional 273,579 shares in the last quarter. Finally, Maverick Capital Ltd. boosted its stake in Vaxcyte by 8.5% in the 2nd quarter. Maverick Capital Ltd. now owns 1,310,605 shares of the company’s stock worth $42,608,000 after purchasing an additional 102,512 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 3.0%

Shares of NASDAQ PCVX opened at $46.59 on Tuesday. The firm’s 50-day moving average price is $46.61 and its 200-day moving average price is $39.77. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $93.77. The company has a market cap of $6.10 billion, a PE ratio of -9.63 and a beta of 1.34.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter in the prior year, the company posted ($0.83) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on PCVX. BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a research note on Monday, November 10th. Needham & Company LLC increased their price target on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. Finally, Leerink Partners set a $77.00 price objective on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.17.

Insiders Place Their Bets

In other news, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the transaction, the senior vice president directly owned 14,534 shares of the company’s stock, valued at $696,469.28. This represents a 44.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the sale, the insider directly owned 23,928 shares of the company’s stock, valued at $1,117,198.32. The trade was a 28.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.10% of the stock is currently owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.